TB remains the world's leading infectious killer, yet the gap widens
Since 2000, the global effort against tuberculosis has saved 83 million lives — a testament to what coordinated human will can accomplish against ancient suffering. Yet at the 79th World Health Assembly in Geneva, delegates acknowledged a harder truth: the current End TB Strategy will not be enough to carry the world past 2030. In response, the WHO Director-General has been charged with crafting a new post-2030 framework, to be presented in 2028, that must reckon not only with scientific progress but with the structural forces — inequality, conflict, underfunding, and climate displacement — that no treatment alone can cure.
- Tuberculosis, the world's leading infectious killer, continues to claim lives at scale even as the 2030 targets set to contain it fall quietly out of reach.
- The pandemic fractured health systems and reversed hard-won gains, and its shadow still distorts the epidemiological landscape TB planners must navigate.
- A record year for TB service access and the first post-pandemic decline in incidence offer genuine hope, but they sit uneasily against chronic underfunding and deepening global inequality.
- The WHO has been tasked with building a new strategy by 2028 — one designed to embed TB response within primary health care and universal coverage rather than treat it as a standalone campaign.
- A deliberate convergence is being engineered: the 2028 strategy presentation is timed to align with a UN High-Level Meeting on TB, creating a rare window where political will and technical planning might briefly occupy the same room.
In late May 2026, delegates gathered in Geneva for the World Health Assembly confronted an uncomfortable reckoning: the world is falling behind on tuberculosis. The assembly's 79th session endorsed a decision to look beyond the current End TB Strategy — whose 2030 targets are slipping — by tasking WHO Director-General Dr Tedros Adhanom Ghebreyesus with developing a new post-2030 framework to be presented to member states in 2028.
The backdrop is one of genuine but insufficient progress. Between 2000 and 2024, expanded TB treatment prevented an estimated 83 million deaths, and 2024 marked the first decline in TB incidence since the pandemic disrupted health systems worldwide. Access to essential services reached record levels. These are achievements that saved entire communities.
And yet TB remains the world's leading infectious killer. The assembly was frank about why targets are slipping: chronic underfunding, the lingering damage of pandemic disruptions, deep structural inequality, armed conflict, and the displacement driven by climate change. These are not problems that better diagnostics alone can solve.
The new strategy will be built with member states and stakeholders, and will seek to weave TB response into the broader fabric of primary health care and universal health coverage — treating it as a systemic challenge rather than a siloed campaign. Its 2028 presentation is timed deliberately to coincide with a UN High-Level Meeting on TB, creating a moment when political attention and technical planning might align. Whether that alignment produces real commitment — in funding and political will — remains the question the strategy itself cannot answer.
In late May, as delegates gathered in Geneva for the World Health Assembly, the conversation turned to an uncomfortable truth: the world is falling behind on tuberculosis. On May 21, 2026, the assembly's 79th session endorsed a decision that amounts to an admission of this gap—and a commitment to plan beyond it. The World Health Organization's Director-General, Dr Tedros Adhanom Ghebreyesus, was tasked with developing a new strategy for the post-2030 era, one that will be presented to the assembly again in 2028.
The timing matters. The current End TB Strategy, which has guided global efforts since 2015, was built around targets meant to be met by 2030. Those targets are slipping. Yet the story is not one of pure failure. Between 2000 and 2024, expanded TB treatment prevented an estimated 83 million deaths. Last year marked the first decline in TB incidence since the pandemic disrupted health systems worldwide. Access to essential TB services reached record levels. These are substantial achievements, the kind that save entire communities from disease.
But TB remains the world's leading infectious killer. The disease still claims lives at scale, and the gap between what has been accomplished and what remains to be done is widening. The new strategy will need to account for emerging scientific advances and shifting epidemiological patterns. It will also need to address what the assembly identified as the real obstacles: chronic underfunding, the lingering effects of pandemic disruptions, deep inequality, armed conflict, and the displacement and vulnerability driven by climate change. These are not technical problems. They are structural ones.
The decision to develop a post-2030 strategy signals that the world's health authorities understand the current approach will not be sufficient. The strategy will be built with input from member states and relevant stakeholders, and it will be designed to reinforce alignment with primary health care, universal health coverage, and global health security. In other words, it will try to embed TB response into the broader architecture of health systems rather than treating it as a separate campaign.
The 2028 World Health Assembly presentation will come just months before a United Nations High-Level Meeting on TB scheduled for that same year. That convergence is deliberate—it creates a moment when political attention and technical planning can align, when countries might be moved to commit resources and political will to a disease that, despite its toll, often competes for attention with more visible crises. The assembly's endorsement in May was a first step. What comes next depends on whether the strategy that emerges will be matched by the funding and political commitment it will require.
Notable Quotes
The new strategy will help guide the future global TB response, considering emerging scientific advances and current epidemiological trends, while reinforcing alignment with primary health care and universal health coverage.— World Health Assembly decision, May 2026
The Hearth Conversation Another angle on the story
Why does the world need a new TB strategy now? Hasn't there been one in place?
There has—the End TB Strategy since 2015. But it was built around targets for 2030, and those targets are falling behind. The world is saying: we need to think beyond 2030, and we need to do it now, while we still have momentum.
What momentum? You said TB remains the leading infectious killer.
True. But 83 million lives saved since 2000 is real. And 2024 was the first year TB incidence actually declined after the pandemic. That's the momentum—not victory, but proof that treatment works when it reaches people.
So what's stopping it from reaching more people?
Money, mostly. Chronic underfunding. But also conflict, climate displacement, inequality. A new strategy can't fix those things alone. It has to be honest about them.
When will this new strategy actually be ready?
2028. Two years from now. It will be presented to the World Health Assembly, and then there's a UN High-Level Meeting on TB that same year. That's when the real test comes—whether countries will actually fund what the strategy calls for.
What makes you think they will?
I don't know that they will. But the fact that they're planning now, acknowledging the gap, building in consultation with member states—that's at least the shape of seriousness. Whether it becomes real depends on what happens next.